Adjuvant T-DM1 for Early HER2+ Breast Cancer Demonstrates Low Recurrence Rate

Article

The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.

Sara Tolaney, MD,  Dana-Farber Cancer Institute

Sara Tolaney, MD, Dana-Farber Cancer Institute

Sara Tolaney, MD

The first reported data for adjuvant T-DM1 (Kadcyla) in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab (Herceptin) and paclitaxel.

Postoperative T-DM1 led to a 3-year disease-free survival (DFS) of 97.7% and 3-year recurrence-free interval (RFI) of 99.1%. Patients with hormone receptor (HR)-positive or HR-negative cancer had similar DFS.1

The 2 treatment arms did not differ with respect to the coprimary endpoint of incidence of clinically relevant toxicity (CRT).

"This represents the first report of patients receiving T-DM1 monotherapy for adjuvant treatment of stage I HER2-positive breast cancer," said Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute in a presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS). "T-DM1 was associated with very few recurrences in the study population. Longer follow-up is needed in a population with predominately hormone receptor-positive disease."

"No difference was seen in the overall incidence of clinically relevant toxicities between the 2 arms, but there were differences in toxicity profiles between T-DM1 and trastuzumab-paclitaxel," added Tolaney, who serves as the associate Director of the Susan F. Smith Center for Women's Cancers and director of Clinical Trials, Breast Oncology at Dana-Farber Cancer Institute. "Given the low event rate seen in this trial, T-DM1 may be an alternative to trastuzumab-paclitaxel for select patients with stage I HER2-positive disease who are concerned about specific trastuzumab-paclitaxel side effects and understand the potential T-DM1 toxicities."

Further evaluation of shorter-duration therapy with T-DM1, followed by trastuzumab, should be considered, said Tolaney.

The rationale for the ATEMPT trial (NCT01853748), came from recognition that some stage I HER2-positive breast cancers have a sufficiently high risk of recurrence to justify adjuvant therapy.2 Trastuzumab and paclitaxel (TH) is associated with a 7-year DFS of 93% in patients with node-negative HER2-positive breast cancer ≤3 cm.3,4

Several studies have shown that T-DM1 has activity in patients with metastatic HER2-positive breast cancer and residual disease after neoadjuvant HER2-directed therapy, Tolaney noted. Additionally, T-DM1 is associated with less toxicity as compared with chemotherapy and trastuzumab.

Investigators in the ATEMPT trial sought to determine whether T-DM1 has a clinically acceptable event rate in patients with stage I HER2-positive breast cancer and whether T-DM1 is associated with less clinically relevant toxicity (CRT) as compared with TH.

The coprimary endpoints were 3-year DFS in the T-DM1 arm and compared incidence of CRTs between T-DM1 and TH. CRTs were defined as grade ≥3 nonhematologic toxicity, grade ≥2 neurotoxicity, grade ≥4 hematologic toxicity, febrile neutropenia, and any toxicity requiring dose delay or discontinuation.

For evaluation of DFS in the T-DM1 arm, the trial had statistical power to distinguish between 3-year failure rates of 9% versus 5%. For the comparison of CRTs, the trial was powered to detect a 40% difference in incidence.

The study population included 497 patients, randomized 2:1 to T-DM1 or TH. Baseline characteristics were balanced between the 2 treatment groups. The patients had a median age of 56, 75% had HR-positive breast cancer, and 73% had 3+ HER2 expression status as determined by fluorescence in situ hybridization.

The trial met the coprimary endpoint of 3-year DFS (P <.0001). The overall DFS of 97.7% included 97.5% in patients with HR-positive disease and 98.5% in HR-negative disease. DFS by tumor size was 98.5% for patients with tumors <1 cm and 97.1% for those with tumors ≥1 cm. DFS events consisted of 7 recurrences (2 ipsilateral, 3 contralateral HER2 negative, and 2 distant) and 3 deaths unrelated to breast cancer.

Although the trial did not compare DFS between the treatment groups, the TH arm had a 3-year DFS of 92.8%. The 7 DFS events consisted of 4 ipsilateral recurrences, 1 new contralateral primary breast cancer, and 2 distant recurrences.

With regard to CRTs, the overall incidence was 46% in both arms. The only notable differences were a higher incidence of neurotoxicity with TH (23% vs 11%) and more toxicity-related early discontinuations with T-DM1 (17% vs 6%).

Overall, 23.5% of patients in the T-DM1 arm discontinued, 17% because of toxicity. Tolaney noted that two thirds of patients who discontinued early for toxicity received additional treatment with trastuzumab. The rate of protocol-mandated discontinuation for toxicity was 9%.

Rates of symptomatic congestive heart failure were 0.8% with T-DM1 and 0.9% with TH. Rates of asymptomatic decline in left ventricular ejection fraction of at least 15% were 1.3% with T-DM1 and 6.1% with TH.

References

  1. Tolaney SM, Hu J, Dang C, et al. TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT). Presented at: 2019 San Antonio Breast Cancer Symposium; December 10-14; San Antonio, TX. Abstract GS1-05.
  2. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700-5706. doi: 10.1200/JCO.2009.23.2025.
  3. Tolaney SM, Barry WT, Dang C, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134-14. doi: 10.1056/NEJMoa1406281.
  4. Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2—positive breast cancer. J Clin Oncol. 2019;37(22):1868-1875. doi: 10.1200/JCO.19.00066.
Related Videos
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Reshma Lillaney Mahtani, DO
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital